The abstract is read at the publisher; the summary is JClub's.
Hepatic AASS silencing via N-acetylgalactosamine–targeted oligonucleotides achieves >90% liver-specific Aass knockdown in wild-type and Aldh7a1 knockout mice, reducing downstream lysine-derived metabolite accumulation.
- Why it matters: ALDH7A1 deficiency and glutaric aciduria type I leave lysine-derived metabolites incompletely controlled, contributing to neurological sequelae, so a substrate-reduction approach targeting upstream AASS is needed.
- What they did: Antisense oligonucleotides and small interfering RNAs against AASS lowered disease-associated metabolites in patient-derived cells, and liver-directed delivery produced sustained Aass protein suppression in mice.
- The result: The knockdown reduced accumulation of downstream lysine-derived metabolites, supporting further evaluation of oligonucleotide-mediated, liver-directed AASS silencing as a substrate reduction strategy for ALDH7A1 deficiency and glutaric aciduria type I.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.